ChunheeRChooMD

PubMed

• 42 citations
  Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer
  William W. Wong, Eric Anderson, Homan Mohammadi, Thomas B. Daniels, S.E. Schild
  Clinical Genitourinary Cancer. 2017-12-01
• 19 citations
  Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Pros...
  Amar U Kishan, Alison Steigler, James W Denham, Almudena Zapatero, Araceli Guerrero
  JAMA Oncology. 2022-03-01
• 13 citations
  Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer.
  Henan Zhang, Jacob J. Orme, F. Abraha, B.J. Stish, Val J. Lowe
  Clinical Cancer Research. 2021-09-30

Journal Articles

• Outcomes and Profiles of Older Patients Receiving Definitive Radiation Therapy for Muscle-Invasive Bladder Cancer at a Tertiary Medical Center  
  Gergelis KR, Kreofsky CR, Choo CS, Viehman J, Harmsen WS, Lester SC, Pisansky TM, Davis BJ, Stish BJ, Choo CR, Practical Radiation Oncology, 2/26/2020
• Is there any benefit in adding postoperative adjuvant concurrent radiotherapy and chemotherapy for penile cancer with regional lymph node metastasis?  
  Choo CR, Nehra A, Zattoni F, Pagliaro LC, Karnes RJ, Minerva, 7/24/2019
• Single-fraction Stereotactic Body Radiation Therapy versus Conventionally Fractionated Radiation Therapy for the Treatment of Prostate Cancer Bone Metastases  
  Gao RW, Olivier KR, Park SS, Davis BJ, Pisansky TM, Choo CR, Kwon ED, Karnes RJ, Harmsen WS, Stish BJ, Advances in Radiation Oncology, 4/1/2019
• IMPT versus VMAT for Pelvic Nodal Irradiation in Prostate Cancer: A Dosimetric Comparison  
  Whitaker TJ, Routman DM, Schultz H, Harmsen WS, Corbin KS, Wong WW, Choo CR, International Journal of Particle Therapy, 3/21/2019
• Outcomes in a multi-institutional cohort of patients treated with intraoperative radiation therapy for advanced or recurrent renal cell carcinoma  
  Paly JJ, Hallemeier CL, Biggs PJ, Niemierko A, Roeder F, Martinez-Monge R, Whitson J, Calvo FA, Fastner G, Sedlmayer F, Wong WW, Ellis RJ, Haddock MG, Choo R, Shipley ..., Int J Radiat Oncol Biol Phys, 1/1/2014
• Late gastrointestinal morbidity in patients with stage I-II testicular seminoma treated with radiotherapy  
  Hallemeier CL, Davis BJ, Pisansky TM, Choo R, Urol Oncol, 1/1/2014
• Excellent long-term disease control with modern radiotherapy techniques for stage I testicular seminoma-the Mayo Clinic experience  
  Hallemeier CL, Choo R, Davis BJ, Leibovich BC, Costello BA, Pisansky TM, Urol Oncol, 1/1/2014
• Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receivin...  
  Choo R, Lukka H, Cheung P, Corbett T, Briones-Urbina R, Vieth R, Ehrlich L, Kiss A, Danjoux C, Int J Radiat Oncol Biol Phys, 1/1/2013
• Multimodality therapy including surgical resection and intraoperative electron radiotherapy for recurrent or advanced primary carcinoma of the urinary bladder or ureter  
  Hallemeier CL, Karnes RJ, Pisansky TM, Davis BJ, Gunderson LL, Leibovich BC, Haddock MG, Choo R, Am J Clin Oncol, 1/1/2013
• Long-term outcomes of radiotherapy for stage II testicular seminoma-the Mayo Clinic experience  
  Hallemeier CL, Pisansky TM, Davis BJ, Choo R, Urol Oncol, 1/1/2013
• Multimodal Treatment Approach to Advanced Female Urethral Squamous Cell Carcinoma  
  Hertiz LL, Choo RC, Lightner DJ, Karnes RJ, Open Journal of Urology, 1/29/2012
• Recommendations for CTV margins in radiotherapy planning for non melanoma skin cancer  
  Khan L, Choo R, Breen D, Assaad D, Fialkov J, Antonyshyn O, McKenzie D, Woo T, Zhang L, Barnes E, Radiother Oncol, 1/1/2012
• Quality of life after hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer  
  Quon H, Cheung PC, Loblaw DA, Morton G, Pang G, Szumacher E, Danjoux C, Choo R, Kiss A, Mamedov A, Deabreu A, Int J Radiat Oncol Biol Phys, 1/1/2012
• Long-term outcomes after maximal surgical resection and intraoperative electron radiotherapy for locoregionally recurrent or locoregionally advanced primary renal cell...  
  Hallemeier CL, Choo R, Davis BJ, Pisansky TM, Gunderson LL, Leibovich BC, Haddock MG, Int J Radiat Oncol Biol Phys, 1/1/2012
• Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity  
  Quon H, Cheung PC, Loblaw DA, Morton G, Pang G, Szumacher E, Danjoux C, Choo R, Thomas G, Kiss A, Mamedov A, Deabreu A, Int J Radiat Oncol Biol Phys, 1/1/2012
• Prostate cancer : Antiandrogen therapy during and after radiation therapy  
  Choo R, Call J, Danjoux C, Oncology Exchange, 1/1/2011
• Vitamin D insufficiency is common in patients with nonmetastatic prostate cancer  
  Choo CS, Mamedov A, Chung M, Choo R, Kiss A, Danjoux C, Nutr Res, 1/1/2011
• Can radiotherapy be a viable salvage treatment option for the relapsed seminoma confined to the infra-diaphragm region recurring after primary chemotherapy for bulky s...  
  Choo R, Quevedo F, Choo CS, Blute M, Can Urol Assoc J, 1/1/2010
• Prospective survey of sexual function among patients with clinically localized prostate cancer referred for definitive radiotherapy and the impact of radiotherapy on s...  
  Choo R, Long J, Gray R, Morton G, Gardner S, Danjoux C, Support Care Cancer, 1/1/2010
• Salvage radiotherapy for patients with PSA relapse following radical prostatectomy: issues and challenges  
  Choo R, Cancer Res Treat, 1/1/2010
• Multiple urinary bladder masses from metastatic prostate adenocarcinoma  
  Hallemeier CL, Kohli M, Chandan VS, Miller RC, Choo R, Rare Tumors, 1/1/2010
• Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse  
  Choo R, Danjoux C, Gardner S, Morton G, Szumacher E, Loblaw DA, Cheung P, Pearse M, Int J Radiat Oncol Biol Phys, 1/15/2009
• Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or posi...  
  Choo R, Danjoux C, Gardner S, Morton G, Szumacher E, Loblaw DA, Cheung P, Pearse M, Int J Radiat Oncol Biol Phys, 1/1/2009
• Analysis of gastrointestinal and genitourinary morbidity of postoperative radiotherapy for pathologic T3 disease or positive surgical margins after radical prostatecto...  
  Choo R, Pearse M, Danjoux C, Gardner S, Morton G, Szumacher E, Loblaw DA, Cheung P, Int J Radiat Oncol Biol Phys, 1/15/2008
• High-dose-rate brachytherapy in the curative treatment of patients with localized prostate cancer  
  Pisansky TM, Gold DG, Furutani KM, Macdonald OK, McLaren RH, Mynderse LA, Wilson TM, Hebl JR, Choo R, Mayo Clin Proc, 1/1/2008
• Join now to see all

Books/Book Chapters

• Prostate Cancer: Balancing the Risks in Diagnosis and Treatment 
  Chapter: Prostate cancer: Palliative care. 
  Iscoe N, Bruera E, Choo REditors: Neill A. Iscoe, Michael A.S. Jewett.Canadian Medical Association1999

Abstracts/Posters

• Long-term outcomes of radiation therapy for stage I testicular seminoma.
  Chunhee Richard Choo, MD, Annual Scientific Meeting, Canadian Association of Radiation Oncologists, Montreal, Quebec, Canada, 1/1/2013
• Concomitant hypofractionated imrt boost for high-risk prostate cancer: 5 year results.
  Cheung P, Loblaw D, Szumacher E, Danjoux C, Choo R, Zhang L, Mamedov A, Deabreu A, Morton G, Int J Radiat Oncol Biol Phys, 1/1/2013
• Late gastrointestinal complications in patients with stage I-II testicular seminoma treated with radiotherapy.
  Hallemeier CL, Davis BJ, Pisansky TM, Choo R, J Clin Oncol, 1/30/2012
• Long-term outcomes of radiotherapy for stage II testicular seminoma-the Mayo Clinic experience.
  Hallemeier CL, Pisansky TM, Davis BJ, Choo R, J Clin Oncol, 1/10/2012
• Long-term outcomes of radiation therapy for stage II testicular seminoma-Mayo Clinic experience.
  Chunhee Richard Choo, MD, Annual Scientific Meeting, Canadian Association of Radiation Oncologists, Ottawa, Ontario, Canada, 1/1/2012
• Long-term outcomes of radiotherapy for stage II testicular seminoma-the Mayo Clinic experience.
  Chunhee Richard Choo, MD, 2012 American Society for Clinical Oncology, Genitourinary Cancer Symposium, San Francisco, CA, 1/1/2012
• Long-term outcomes of radiation therapy for stage II testicular seminoma.
  Hallemeier CL, Pisansky TM, Davis BJ, Choo R, Int J Radiat Oncol Biol Phys, 1/1/2012
• Long-term outcomes of radiotherapy for stage II testicular seminoma-Mayo Clinic experience.
  Choo CR, Hallemeier C, Radiother Oncol, 1/1/2012
• How should locoregionally recurrent or advanced primary malignacies of the bladder or ureter be managed? Potential role of multimodality therapy incorporating surgery ...
  Choo R, Hallemeier C, Haddock M, Can Urol Assoc Journal, 1/1/2012
• Multimodality therapy including surgical resection and intraoperative electron radiotherapy for locally recurrent or advanced primary malignancies of the urinary bladd...
  Hallemeier CL, Karnes R, Pisansky T, Davis B, Gunderson L, Leibovich B, Haddock M, Choo R, J Clin Oncol, 1/29/2011
• Seminal vesicle invasion at the time of prostatectomy: Correlation of prostate cancer specific survival with clinical and pathologic findings.
  Call JA, Davis BJ, Hillman DW, Carlson RE, Choo CR, 3rd European Multidisciplinary Meeting on Urological Cancers (organized by the European Association of Urology (EAU) European Society of Medical Oncology (ESMO), and European Society of Therapeutic Radiation Oncology (ESTRO), Barcelona, Spain, 1/4/2011
• Long-term outcomes after maximal surgical resection and intraoperative electron radiotherapy for locoregionally recurrent or locoregionally advanced primary renal cell...
  Chunhee Richard Choo, MD, Annual Scientific Meeting, Canadian Association of Radiation Oncologists, Winnipeg, Manitoba, Canada, 1/1/2011
• Quality of life after pelvic radiotherapy with hypofractionated IMRT boost and long-term hormone therapy for locally advanced prostate cancer.
  J Clin Oncol; American Society of Clinical Oncology Genitourinary Cancers Symposium, 1/1/2011
• Double-blinded, placebo-controlled randomized study evaluating the efficacy of risedronate to prevent the loss of bone mineral density in non-metastatic prostate cance...
  Choo C, Lukka H, Kiss A, Danjoux C, Int J Radiat Oncol Biol Phys, 1/1/2011
• Phase III, double-blinded, placebo-controlled, study evaluating the efficacy of risedronate to prevent the loss of bone mineral density in non-metastatic prostate canc...
  Choo R, Lukka H, Briones-Urbina R, Reinhold V, Azad A, Ehrich L, Kiss A, Danjoux C, Radiother Oncol, 1/1/2011
• Long-term outcomes after maximal surgical resection and intraoperative electron radiotherapy for locoregionally recurrent or locoregionally advanced primary renal cell...
  Choo R, Hallemeier C, Haddock M, Radiother Oncol, 1/1/2011
• Recommendations for CTV margins in radiotherapy planning for nonmelanoma skin cancer.
  Khan L, Choo R, Breen D, Assad D, Fialkov J, Antonyshyn O, McKenzie D, Woo T, Zhang L, Barnes E, Radiother Oncol, 1/1/2011
• Vitamin D insufficiency is common among prostate cancer patients.
  Chunhee Richard Choo, MD, Annual Scientific Meeting, Canadian Association of Radiation Oncologists, Vancouver, British Columbia, Canada, 1/1/2010
• Maximal surgical resection and intraoperative electron radiotherapy for locoregionally recurrent or locoregionally advanced renal cell carcinoma.
  Hallemeier CL, Choo R, Gunderson LL, Leibovich BC, Haddock MG, The 6th International Conference of the International Society of Intraoperative Radiation Therapy, 1/1/2010
• Prospective study of pelvic radiotherapy with concomitant hypofractionated accelerated IMRT boost for localized high-risk prostate cancer: Acute and late toxicities.
  Quon H, Loblaw D, Morton G, Szumacher E, Danjoux C, Choo R, Thomas G, Kiss A, Deabreu A, Cheung P, J Clin Oncol; American Society of Clinical Oncology Genitourinary Cancers Symposium, 1/1/2010
• Patient reported outcomes after hypofractionated radiotherapy and long-term androgen deprivation for high-risk prostate cancer.
  Quon HC, Loblaw DA, Morton G, Szumacher E, Danjoux C, Choo R, Thomas G, Kiss A, Deabreu A, Cheung PCF, Int J Radiat Oncol Biol Phys, 1/1/2010
• Long-term outcomes of the combined approach of maximal surgical resection and intraoperative electron radiotherapy for recurrent or locally advanced renal malignancies.
  Hallemeier CL, Choo R, Gunderson LL, Leibovich BC, Haddock MG, Int J Radiat Oncol Biol Phys, 1/1/2010
• Phase I/II trial of combined hormonal therapy and hypofractionated accelerated radiotherapy with concomitant intensity-modulated boost for high-risk prostate cancer: t...
  Quon H, Loblaw D, Morton G, Szumacher E, Danjoux C, Choo R, Thomas G, Kiss A, Deabreu A, Cheung P, J Clin Oncol, 1/1/2010
• Acute and late toxicity of pelvic radiotherapy and concomitant hypofractionated IMRT boost combined with hormonal therapy for high-risk prostate cancer.
  Quon H, Loblaw D, Morton G, Sixel K, Pang G, Basran P, Szumacher E, Danjoux C, Choo R, Thomas G, Kiss A, Deabreu A, Cheung P, Radiother Oncol, 1/1/2010
• Vitamin D insufficiency is common in patients with nonmetastatic prostate cancer.
  Choo R, Danjoux C, Choo CS, Kiss A, Radiother Oncol, 1/1/2010
• Join now to see all

Lectures

• Trimodality therapy for bladder cancer. 
  Seoul, South Korea - 1/1/2014
• Update on a trimodality therapy in bladder cancer. 
  Seoul, South Korea - 1/1/2014
• Update on radiation treatment for invasive bladder cancer. 
  Kohala Coast, HI - 1/1/2014
• External beam radiotherapy versus brachytherapy for early prostate cancer. 
  Santiago, Chile - 1/1/2014
• Conservative treatment of invasive bladder cancer: radiotherapy plus chemotherapy. 
  Santiago, Chile - 1/1/2014
• Radiotherapy of clinically localized prostate carcinoma: Evidence-based approach for low-risk, intermediate-risk, and high-risk carcinoma. 
  Center of Medical Physics and Technology, Hefei Institutes of Physical Science, Chinese Academy of S - 1/1/2013
• Evidence based approach for radiotherapy of low, intermediate, and high risk prostate cancer. 
  Muscat, Oman - 1/1/2013
• Debate: Is organ preservation viable in bladder cancer? 
  Muscat, Oman - 1/1/2013
• Debate: Point-Counterpoint: Optimal management approach for locally advanced prostate cancer. 
  Chicago, IL - 1/1/2012
• Organ preservation strategy for muscle-invasive bladder carcinoma. 
  Bangkok, Thailand - 1/1/2012
• Risk-based approach for the radiotherapy of prostate carcinoma, using clinical evidences. 
  Bangkok, Thailand - 1/1/2012
• Risk-based approach for the radiotherapy of prostate carcinoma. 
  Samsung Medical Center, Department of Radiation Oncology, Sungkyunkwan University, Seoul, South Kore - 1/1/2012
• Long-term outcomes of radiation therapy for stage II testicular seminoma. 
  Boston, MA - 1/1/2012
• How should locoregionally recurrent or advanced primary malignacies of the bladder or ureter be managed? Potential role of multimodality therapy incorporating surgery ... 
  Banff, Alberta, Canada - 1/1/2012
• Raiotherapist's view: evidence-based approach for the radiotherapy of prostate cancer. 
  Santiago, Chile - 1/1/2011
• Double-blinded, placebo-controlled, randomized study evaluating the efficacy of risedronate to prevent the loss of bone mineral density in non-metastatic prostate canc... 
  Miami Beach, FL - 1/1/2011
• Phase III, double-blinded, placebo-controlled, study evaluating the efficacy of risedronate to prevent the loss of bone mineral density in non-metastatic prostate canc... 
  Winnipeg, Manitoba, Canada - 1/1/2011
• Organ-preservation strategy for muscle-invasive bladder carcinoma. 
  Santiago, Chile - 1/1/2011
• Salvage radiotherapy for PSA relapse following radical prostatectomy: current status. 
  Santiago, Chile - 1/1/2011
• Organ-preservation strategy for bladder cancer. (Visiting Professor) 
  Samsung Medical Center, Department of Radiation Oncology, Sungkyunkwan University, Seoul, South Kore - 1/1/2010
• Active Surveillance for Low Risk, Localized, Prostate Cancer 
  Rochester, MN - 1/1/2010
• Advance and clinical application of IGRT for prostate cancer. 
  Seoul, South Korea - 1/1/2010
• Management of PSA Relapse after Radical Prostatectomy. (Visiting Professor) 
  Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Ca - 1/1/2009
• Radiotherapy options for prostate cancer. 
  Rochester, MN - 1/1/2009
• Prospective study evaluating salvage radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with PSA relapse. 
  Chicago, IL - 1/1/2009
• Join now to see all

Other

• Combining hormone therapy with radiation for the treatment of prostate cancer. 
  Choo R, Together, Mayo Clinic Cancer Center
  1/1/2005
• Androgen ablation for metastatic prostate cancer. 
  Choo R, Hot Spot
  1/1/2003
• Expanded role of hormone therapy as neoadjuvant or adjuvant therapy in prostate cancer patients undergoing definitive treatment. 
  Choo R, Hot Spot
  1/1/2002
• Clinically localized prostate cancer: to treat or not to treat? 
  Choo R, Danjoux C, Morton G, Flavin A, Cancer Record (Statistics Canada)
  1/1/1996
• Brachytherapy: alternative treatment for penile carcinoma. 
  Choo R, Danjoux C, Balogh J, Focus on Oncology
  1/1/1992
• Join now to see all